Zynex (NASDAQ:ZYXI) Issues Quarterly Earnings Results

Zynex (NASDAQ:ZYXI) released its quarterly earnings data on Thursday. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01, Briefing.com reports. The business had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. Zynex had a return on equity of 14.15% and a net margin of 3.12%. The company’s revenue was up .1% on a year-over-year basis. During the same quarter last year, the business posted $0.10 EPS.

Zynex Price Performance

Shares of NASDAQ:ZYXI traded up $0.37 during trading on Friday, reaching $8.96. 133,969 shares of the company’s stock traded hands, compared to its average volume of 173,262. The company has a quick ratio of 3.22, a current ratio of 4.06 and a debt-to-equity ratio of 1.79. Zynex has a fifty-two week low of $7.04 and a fifty-two week high of $13.77. The company has a 50-day simple moving average of $7.96 and a 200-day simple moving average of $9.23. The firm has a market cap of $284.39 million, a PE ratio of 51.72 and a beta of 0.54.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. HC Wainwright lifted their price target on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday. Royal Bank of Canada cut their target price on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Insider Buying and Selling at Zynex

In other Zynex news, Director Joshua R. Disbrow bought 7,000 shares of Zynex stock in a transaction dated Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, with a total value of $58,240.00. Following the purchase, the director now directly owns 72,000 shares in the company, valued at $599,040. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In related news, COO Anna Lucsok sold 8,083 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares in the company, valued at approximately $136,349.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joshua R. Disbrow bought 7,000 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were acquired at an average cost of $8.32 per share, with a total value of $58,240.00. Following the acquisition, the director now directly owns 72,000 shares of the company’s stock, valued at approximately $599,040. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 52.13% of the stock is owned by corporate insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.